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Summary
Background: Non-nucleoside reverse transcriptase inhibitor (NNRTI)-based highly active anti-
retroviral therapy (HAART) has been the most affordable regimen for the HIV-infected in
developing countries. There are limited data comparing nevirapine (NVP) to efavirenz (EFV)
in HIV-infected children. This study aimed to assess the efficacy and tolerability of NVP-based
regimens compared to EFV-based regimens in HIV-infected children in Thailand.
Methods: The medical records of HIV-infected children who had received NNRTI-based regimens
for more than 6 months at the Department of Pediatrics, Siriraj Hospital, Mahidol University,
Thailand, were reviewed.
Results: Of the 139 HIV-infected children studied, 70 were male, and the median age at
treatment initiation was 6.08 years (range 0.32—14.56 years); the median duration of follow-
up was 36 months (range 6—66 months). The median baseline CD4 cell count was 185 cells/mm3
(range 2—3482 cells/mm3) and the median baseline CD4 percentage was 7.20% (range 0.11—
36.57%). An NVP-based regimen was initiated in 61 (44%): 38 antiretroviral (ARV)-naı¨ve and 23
ARV-experienced. An EFV-based regimen was initiated in 78 (56%): 34 ARV-naı¨ve and 44 ARV-
experienced. The CD4 cell count and percentage gains were not different between the NVP and
EFV groups in both the ARV-naı¨ve and the ARV-experienced. However, ARV-naı¨ve children who
received an EFV regimen had significantly lower baseline CD4 levels than those who received an
NVP regimen. ARV-naı¨ve children had a better CD4 response than the ARV-experienced. The
survival rates of children in the NVP groups were not different from those in the EFV groups for
both the ARV-naı¨ve and the ARV-experienced. Treatment failure occurred in one ARV-naı¨ve NVP
case (2.6%), two ARV-naı¨ve EFV cases (5.8%), and nine ARV-experienced NVP cases (39%) at 24
months of treatment, and 11 ARV-experienced EFV cases (25%) at 18 months of treatment. Seven* Corresponding author. Tel.: +66 2 4180544; fax: +66 2 4180544.
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1201-9712/$32.00 # 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
doi:10.1016/j.ijid.2007.10.008
(10%) children had adverse effects from treatment with NVP. The main side effects were rash and
hepatitis; six had to switch to EFV. Four (5%) children had adverse effects from treatment with EFV;
two had to switch to NVP.
Conclusions: Both NVP- and EFV-based HAARTregimens were effective in children in Thailand for at
least 3 years. HIV-infected Thai children generally tolerated NNRTI well.
# 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Non-nucleoside reverse transcriptase inhibitor (NNRTI)-
based highly active antiretroviral therapy (HAART) has been
the most affordable regimen for the HIV-infected in devel-
oping countries. In Thailand, the preferred first-line regimen
for HIV-infected adults and children is nevirapine (NVP)-
based HAART due to the availability of generic drugs. Efavir-
enz (EFV)-based HAART has been used in those who are
unable to tolerate NVP. Both NVP- and EFV-containing regi-
mens have been shown in adults to be as effective in reducing
viral loads and improving CD4 cell counts as protease inhi-
bitor (PI)-containing regimens.1 Previous studies comparing
NVP-based and EFV-based regimens in adult patients have
shown comparable effectiveness. However, some studies
have shown the superiority of EFV.2—5 There are limited data
comparing NVP to EFV in HIV-infected children. This study
aimed to assess the efficacy and tolerability of NVP-based
regimens compared to EFV-based regimens in HIV-infected
children in Thailand.
Materials and methods
The medical records of HIV-infected children who had
received either NVP or EFV plus two nucleoside reverse
transcriptase inhibitors (NRTIs) for more than 6 months at
the Department of Pediatrics, Siriraj Hospital, Bangkok,
Thailand, were reviewed. Administration of the antiretro-
viral (ARV) agents was supported by the Thai Ministry of
Public Health (MOPH). The treatment regimens were decided
upon, mainly based on drug availability, by the National
Access to Antiretroviral Program for People Living with
HIV/AIDS (NAPHA). In general, NVP has been the first line
regimen of choice for all. EFV has been used in children over 3
years of age, particularly children who are not able to
tolerate NVP.
All the NRTIs and NVP were produced locally by the
Government Pharmaceutical Organization (GPO); EFV was
from Merck. Whenever possible, the fixed-dose combination
(FDC) for adults containing stavudine (d4T)/lamivudine
(3TC)/NVP (GPO-VIR1 S30) was used by breaking the tablet
to achieve an NVP dosage of 120—200 mg/m2/dose. During
the first 14 days of NVP initiation, the dose was given once
daily in the morning. Serum transaminase was checked
before treatment and on day 14 after treatment. If there
were no problems, the dosing with NVP was increased to
every 12 hours. Serum transaminase was checked every 6
months afterwards, or if clinically indicated. The dosage of
EFV was 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, and
600 mg q 24 h at bedtime for children with body weights
of 10 to <15 kg, 15 to <20 kg, 20 to <25 kg, 25 to <32.5 kg,
32.5 to <40 kg, or 40 kg, respectively, as recommended inthe US guidelines.6 The patients were followed up every 1—2
months.
Laboratory monitoring including complete blood count,
CD4 cell count, and CD4%, were performed at baseline and
every 6 months. Viral load was not available from the NAPHA
program. Adverse drug reactions weremonitored. Adherence
was assessed by pill counts and self-reports. Treatment fail-
ure necessitating changes to the ARV regimen were based on
clinical and immunological considerations according to the
Centers for Disease Control and Prevention (CDC) guidelines.7
The clinical stages of disease were stratified according to the
1994 CDC revised classification system.8 The weight for age z-
score (z-W/A) and height for age z-score (z-H/A) were cal-
culated by Epi-Info program (version 3.3.2) using anthropo-
metric data (1978 CDC/World Health Organization (WHO)
growth reference).
The patients were classified into four groups: (1) ARV-
naı¨ve before receiving NVP-based regimens (naı¨ve-NVP); (2)
failed dual NRTI regimen before switching to NVP-based
regimens (exp-NVP); (3) ARV-naı¨ve before receiving EFV-
based regimens (naı¨ve-EFV); and (4) failed dual NRTI regimen
before switching to EFV-based regimens (exp-EFV). For the
experienced children who switched from dual NRTI to NVP-
based or EFV-based regimens, genotype testing was not
performed.
Data analysis
The data were analyzed using SPSS version 11.5 (SPSS, Chi-
cago, IL, USA). Descriptive statistics were used to describe
demographic data, the z-W/A and z-H/A gain, and the CD4
cell count and percentage gain of each group. Comparisons
between groups were performed using one-way ANOVA tests
or Kruskal—Wallis tests and post-hoc multiple comparison
tests. The differences between NVP and EFV and the differ-
ences between the naı¨ve and experienced groups were com-
pared by independent sample t-tests. The survival rate of
each treatment regimen was analyzed by intention-to-treat
manner using Kaplan—Meier analysis with log rank test for
comparison.
Results
From September 1996 to July 2006, 139 HIV-infected children
were treated with NVP or EFV. Of the 139 children, 70 (50%)
were male and 137 (98.5%) had been perinatally infected.
The median age at treatment initiation was 6.08 years (range
0.32—14.56 years). The median baseline CD4 cell count was
185 cells/mm3 (range 2—3482 cells/mm3) and the median
baseline CD4 percentage was 7.20% (range 0.11—36.57%).
An NVP-based regimen was initiated in 61 (44%): 38 ARV-naı¨ve
(naı¨ve-NVP) and 23 ARV-experienced (exp-NVP). An EFV-
Table 1 Baseline characteristics of the patients before receiving either nevirapine- or efavirenz-based HAART regimens
All patients
(N = 139)
Naı¨ve-NVP
(N = 38)
Exp-NVP
(N = 23)
Naı¨ve-EFV
(N = 34)
Exp-EFV
(N = 44)
p-Value
Median age (years) 6.08 4.56 7.4 6.4 5.7 0.196
Male 70 (50%) 14 (37%) 12 (52%) 21 (62%) 23 (52%) 0.200
Female 69 (50%) 24 (63%) 11 (48%) 13 (38%) 21 (48%)
Clinical staging N = 8 (6%) N = 4 (10%) N = 0 N = 1 (3%) N = 3 (7%) 0.402
A = 28 (20%) A = 6 (16%) A = 7 (30%) A = 5 (15%) A = 10 (23%)
B = 58 (42%) B = 16 (42%) B = 10 (44%) B = 12 (35%) B = 20 (45%)
C = 45 (32%) C = 12 (32%) C = 6 (26%) C = 16 (47%) C = 11 (25%)
Immunological staging 1 = 6 (4%) 1 = 4 (10%) 1 = 0 1 = 1 (3%) 1 = 1 (2%) 0.051
2 = 19 (14%) 2 = 9 (24%) 2 = 3 (13%) 2 = 1 (3%) 2 = 6 (14%)
3 = 114 (82%) 3 = 25 (66%) 3 = 20 (87%) 3 = 32 (94%) 3 = 37 (84%)
Median duration of ARVa
before initiation of
HAART (months)
30 (3—81) NA 32 (4—78) NA 29 (3—81) 0.857
Median CD4 cells count 185 (2—3482) 266 (2—3482) 290 (28—1280) 27.5 (2—1632) 253 (2—1873) 0.004b
0.677c
Median CD4 percentage 7.20
(0.11—36.57)
10.89
(0.23—36.57)
10.77
(0.82—27.29)
1.43
(0.11—31.46)
9.55
(0.18—30.86)
0.005b
0.411c
Number of cases with
OIs before HAART
40 15 3 19 3
Tuberculosis 11 2 16 3
MAC + NTM 2 1 1 0
PCP 1 0 1 0
CMV retinitis 3 0 1 0
Cryptococcosis 1 0 1 0
Penicillosis 0 0 1 0
Median follow-up time
(months)
36 (6—66) 30 (12—48) 36 (6—42) 36 (18—66) 42 (12—66) 0.000
NVP, nevirapine; EFV, efavirenz; ARV, antiretroviral; HAART, highly active antiretroviral therapy; NA, not applicable; OIs, opportunistic
infections; MAC, Mycobacterium avium complex; NTM, non-tuberculous mycobacteria; PCP, Pneumocystis carinii pneumonia; CMV = cy-
tomegalovirus; NRTI, nucleoside reverse transcriptase inhibitor.
Naı¨ve-NVP = ARV-naı¨ve before receiving NVP-based regimens; exp-NVP = failed dual NRTI regimen before switching to NVP-based regimens;
naı¨ve-EFV = ARV-naı¨ve before receiving EFV-based regimens; exp-EFV = failed dual NRTI regimen before switching to EFV-based regimens.
a ARV = mono or dual NRTI treatment.
b p for naı¨ve-NVP vs. naı¨ve-EFV.
c p for exp-NVP vs. exp-EFV.
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EFV) and 44 ARV-experienced (exp-EFV). The patients in the
EFV groups had lower baseline CD4 cell counts and CD4
percentages than those in the NVP groups, and the naı¨ve-
EFV group had the lowest CD4 level (Table 1). The median
duration of follow-up was 36 months (range 6—66 months).
Three patients in the naı¨ve-NVP group were referred to
other centers after a median treatment duration of 24
months; one patient in the naı¨ve-EFV group was referred
after 42 months and four patients in the exp-EFV group were
referred after a median of 36 months. Five patients in the
naı¨ve-EFV group and six patients in the exp-EFV group had to
switch from EFV to NVP due to EFV shortage after a median
duration of 22 months (range 11—40 months). The data for
these patients after switching to NVP were not included in
the analysis. To date, all of these patients still maintain good
clinical and immunological responses after having been
switched for more than 18 months. The percentage of chil-
dren who took 90% of their dispensed medications, verifiedby pill count, was 88% (87.5% for the NVP-based regimen vs.
88.7% for the EFV-based regimen; p = 0.926).
AIDS-related illnesses before HAARTwere more prevalent
in the naı¨ve groups than in the experienced groups (Table 1).
Twenty-nine of 34 patients (85%) in the naı¨ve groups who had
opportunistic infections (OIs) had onset before initiation of
HAART. The other five patients (three with tuberculous lym-
phadenitis, one with Mycobacterium fortuitum and Nocardia
lymphadenitis, and one withMycobacterium avium complex)
developed OIs at a median duration of 3 weeks (range 1—7
weeks) following HAART initiation. All of these patients had
low baseline CD4 cell counts (median 27 cells/mm3, range 2—
343 cells/mm3) and CD4 percentages (median 2.07%, range
0.23—12.4%). In all six patients with OIs in the experienced
groups, these developed while on mono or dual NRTIs before
initiation of HAART. No patient died from an AIDS-related
illness.
The median gains in z-W/A and z-H/A after HAART in the
naı¨ve groups were higher than in the experienced groups, but
Figure 1 Median CD4% gain at 6, 12, 18, 24, 30, and 36 months
after initiation of NNRTI-based HAART. p = 0.942 for naı¨ve-NVP
vs. naı¨ve-EFV; p = 0.266 for exp-NVP vs. exp-EFV. Naı¨ve-
NVP = ARV-naı¨ve before receiving NVP-based regimens; exp-
NVP = failed dual NRTI regimen before switching to NVP-based
regimens; naı¨ve-EFV = ARV-naı¨ve before receiving EFV-based
regimens; exp-EFV = failed dual NRTI regimen before switching
to EFV-based regimens.
Figure 3 Survival curve of treatment failure. Number of
patients = 137, 133, 111, and 56 at 6, 12, 24, and 36 months,
respectively. p = 0.5151 for naı¨ve-NVP vs. naı¨ve-EFV; p = 0.2199
for exp-NVP vs. exp-EFV. Naı¨ve-NVP = ARV-naı¨ve before receiving
NVP-based regimens; exp-NVP = failed dual NRTI regimen before
switching to NVP-based regimens; naı¨ve-EFV = ARV-naı¨ve before
receiving EFV-based regimens; exp-EFV = failed dual NRTI regi-
men before switching to EFV-based regimens.
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Likewise, the naı¨ve groups had higher CD4 cell count and
percentage gains than the experienced groups ( p < 0.0001).
However, the CD4 cell count and percentage gain were not
different between naı¨ve-NVP vs. naı¨ve-EFV and exp-NVP vs.
exp-EFV groups at 36 months of treatment ( p = 0.729 for CD4
cell count and p = 0.942 for CD4 percentage in naı¨ve-NVP vs.
naı¨ve-EFV; p = 0.388 for CD4 cell count and p = 0.266 for CD4
percentage in exp-NVP vs. exp-EFV; Figures 1 and 2).
Theratesof treatment failure forchildren in theNVPgroups
were not different from those in the EFV groups. However, the
rates of treatment failure in the ARV-naı¨ve groups were lower
than in the ARV-experienced groups (p = 0.0002 for naı¨veFigure 2 Median CD4 number gain at 6, 12, 18, 24, 30, and 36
months after initiation of NNRTI-based HAART. p = 0.729 for
naı¨ve-NVP vs. naı¨ve-EFV; p = 0.388 for exp-NVP vs. exp-EFV.
Naı¨ve-NVP = ARV-naı¨ve before receiving NVP-based regimens;
exp-NVP = failed dual NRTI regimen before switching to NVP-
based regimens; naı¨ve-EFV = ARV-naı¨ve before receiving EFV-
based regimens; exp- EFV = failed dual NRTI regimen before
switching to EFV-based regimens.groups vs. experienced groups; Figure 3). One naı¨ve-NVP case
(2.6%) and two naı¨ve-EFV cases (5.8%) met the criteria of
treatment failure after 24 months of treatment. On the other
hand, nine of the exp-NVP cases (39%) had treatment failure at
24 months and 11 of the exp-EFV cases (25%) had treatment
failure at 18 months of treatment.
Seven (10%) children had adverse effects fromNVP; six (9%)
had to switch to EFV. All seven children had a rash; twoalso had
hepatitis and two also had fever. The rash in two children
involved the mucous membranes. However, none progressed
to Stevens—Johnson syndrome, and all responded well to drug
interruption with antihistamine. Prednisolone was given in
three cases. One child had asymptomatic hepatitis
(ALT = 162 U/l) without rash but tolerated the re-challenged
NVP. Four children (5%) had adverse effects from EFV. Two
children had sleep problems and nightmares. However, they
were able to tolerate the EFV thereafter. Another two children
had vomiting andwere successfully switched toNVP. Sixty-nine
of 113 children (61%) for whom a lipid profile was available
experienced dyslipidemia. Hypercholesterolemia with hyper-
low density lipoprotein (hyper-LDL) and hypo-high density
lipoprotein (hypo-HDL)was found in 33%and19%, respectively.
Seven patients developed visible peripheral lipoatrophy. The
mean age of onset of lipodystrophy was 9.8 years (range 6.2—
16.6 years). All had received d4T for more than 28 months.
Discussion
Our data suggest that both NVP- and EFV-based regimens
were effective in treatment-naı¨ve children. The CD4 gain and
rate of treatment failure were not different between the two
regimens. EFV-based regimens may be more effective, con-
sidering that baseline CD4 levels in the naı¨ve-EFV were lower
than in the naı¨ve-NVP group. We also found that the rate of
treatment failure in ARV-naı¨ve children in the EFV group was
not different from that in the NVP group; however, the
sample size in this study may have been too small to detect
the difference.
Several randomized clinical trials in ARV therapy-naı¨ve
adult patients have shown that the regimens containing an
Nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children e37NNRTI are at least as effective as regimens that include a
PI.9—11 One cohort study in ARV-naı¨ve Thai adult patients with
advanced HIV infection showed that NVP- and EFV-based
HAARTregimens were equally effective in terms of virological
and immunological responses.12 However, three large cohort
studies comparing EFV-based HAARTwith NVP-based HAART in
ARV-naı¨ve adult patients showed a superiority of EFV.2—4 A
recent cohort study demonstrated the effectiveness of
NNRTI-based HAART regimens in treatment-naı¨ve Thai chil-
dren with advanced stage HIV infection.13,14 This cohort
study showed that the patients who received EFV-based
regimens had a higher rate of virological suppression than
those who received NVP-based regimens (83% vs. 61%) at 4
years.13,14 However, the children in the NVP group were
younger than those in the EFV group, and more children in
the NVP group were at stage C of the disease. Another well-
designed randomized trial in ARV-naı¨ve adults (the 2NN
study) found that the rate of treatment failure was not
statistically significant between the NVP arm and the EFV
arm (43.7% vs. 37.8%).5 However, in the patients with base-
line CD4 cell counts <25  106 cells/l, EFV tended to be
superior in viral load suppression.15 Overall, EFV may be
more effective than NVP.
Experiences of ARV therapies before initiation of HAART
have been associated with virological and immunological
failure both in adults and in children.16—19 Our study found
that the ARV-naı¨ve group response was better than that of the
ARV-experienced group. A recent report that supports our
study is an observational study of 95 vertically HIV-infected
children. It assessed the viral loads and CD4 percentage after
48 months of HAART and showed that previous ARV therapy
affects the overall response to subsequent HAART.20
A study from the Pediatric AIDS Clinical Trials Group 382
Team in ARV-experienced children found that EFV was
better than NVP.21 The report of a cross-sectional study
on 95 HIV-infected Thai children who had received dual
NRTI therapy for at least 6 months showed a high preva-
lence of NRTI resistance mutations; 96.8% had resistance to
at least one NRTI and approximately half of the children
had resistance to multiple NRTIs.22 Therefore the choice of
NRTI in salvage therapy would be limited. The regimen of
two NRTIs plus NNRTI would not be very effective, as
found in our study; almost one third of those in the
experienced groups failed with two NRTIs plus NNRTI within
3 years.
The main side effects of NVP were rashes and hepatitis.
Previous studies in 74 children in the UK and 61 children in
Thailand reported that NVP caused a rash in 20—23% and
hepatitis in 9—15% of children, respectively.13,23,24 Themajor
side effect of EFV was dysphoria, including vivid dreams,
depression, drowsiness, and insomnia, which might be under-
estimated and difficult to assess in children. Other previous
studies in 46 children in Thailand and 33 in the USA reported
transient central nervous system disturbance after receiving
EFV in 26—36% and rash in 7—15% of patients, respec-
tively.13,25 The adverse reactions to NVP and EFV in our study
were similar to those of other reports, but with a much lower
frequency. Severe rashes were found more often in those on
NVP-based than EFV-based regimens.
Our study has several limitations; it was retrospective,
unblinded, with different uncontrolled baseline character-
istics such as staging, CD4 cell count and percentage, z-W/Aand z-H/A, etc. It did not have adequate power to assess
differences in NVP and EFV efficacy. We did not monitor viral
load in the routine service and therefore this study had no
data regarding the virological response.
Conclusions
Both NVP- and EFV-based HAARTwere effective in children in
Thailand for at least 3 years. HIV-infected Thai children
generally tolerated NNRTI well withmanageable side effects.
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